Merck to gain fast-selling COPD therapy via $10B Verona buyout

In Robert Davis’ third 11-figure deal since ascending to the CEO role in 2021, Merck is paying $10 billion to obtain a fast-growing therapy for COPD via the acquisition of London-based Verona.

The price makes it the biggest deal ever for a U.K.-based biotech, according to BioCentury’s BCIQ database. It will doubtless provide a morale boost for the growing U.K. biotech arena, coupled with the opportunity to recycle talent into a sector in need of experienced management talent...